Search details
1.
Pulmonary function is a strong predictor of 2-year overall survival and non-relapse mortality after allogenic hematopoietic cell transplantation.
Eur J Haematol
; 110(1): 50-59, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36153797
2.
Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors.
Blood
; 136(13): 1499-1506, 2020 09 24.
Article
in English
| MEDLINE | ID: mdl-32603426
3.
Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population-based cohort study.
Br J Haematol
; 200(4): e40-e43, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36263998
4.
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
Br J Haematol
; 178(4): 521-533, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28589551
5.
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Br J Haematol
; 175(3): 410-418, 2016 Nov.
Article
in English
| MEDLINE | ID: mdl-27378674
6.
Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire.
Biol Blood Marrow Transplant
; 21(8): 1515-23, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-25958294
7.
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Br J Haematol
; 158(3): 355-62, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-22640180
8.
Single-institution long-term outcomes for patients receiving nonmyeloablative conditioning hematopoeitic cell transplantation for chronic lymphocytic leukemia and follicular lymphoma.
Eur J Haematol
; 89(2): 151-9, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-22574687
9.
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.
Blood
; 112(7): 2687-93, 2008 Oct 01.
Article
in English
| MEDLINE | ID: mdl-18625886
10.
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
Bone Marrow Transplant
; 54(1): 44-52, 2019 01.
Article
in English
| MEDLINE | ID: mdl-29728701
11.
Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma.
Exp Hematol
; 30(7): 703-10, 2002 Jul.
Article
in English
| MEDLINE | ID: mdl-12135667
12.
Pretransplantation vitamin A plasma levels and risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplant
; 55(7): 1457-1459, 2020 07.
Article
in English
| MEDLINE | ID: mdl-31772337
13.
Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
J Clin Oncol
; 27(26): 4365-70, 2009 Sep 10.
Article
in English
| MEDLINE | ID: mdl-19652064
14.
Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant.
Eur J Haematol
; 71(2): 73-80, 2003 Aug.
Article
in English
| MEDLINE | ID: mdl-12890145
Results
1 -
14
de 14
1
Next >
>>